Immunic Inc. (IMUX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Immunic Statistics
Share Statistics
Immunic has 90.08M shares outstanding. The number of shares has increased by 0.17% in one year.
Shares Outstanding | 90.08M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 87.36M |
Failed to Deliver (FTD) Shares | 15.09K |
FTD / Avg. Volume | 1.55% |
Short Selling Information
The latest short interest is 4.91M, so 5.45% of the outstanding shares have been sold short.
Short Interest | 4.91M |
Short % of Shares Out | 5.45% |
Short % of Float | 5.62% |
Short Ratio (days to cover) | 6.07 |
Valuation Ratios
The PE ratio is -0.71 and the forward PE ratio is -1.8.
PE Ratio | -0.71 |
Forward PE | -1.8 |
PS Ratio | 0 |
Forward PS | 0.6 |
PB Ratio | 2.3 |
P/FCF Ratio | -0.93 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immunic Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 0.05.
Current Ratio | 2.12 |
Quick Ratio | 2.12 |
Debt / Equity | 0.05 |
Total Debt / Capitalization | 4.41 |
Cash Flow / Debt | -53.09 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.24% and return on capital (ROIC) is -327.85%.
Return on Equity (ROE) | -3.24% |
Return on Assets (ROA) | -1.72% |
Return on Capital (ROIC) | -327.85% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.10M |
Employee Count | 85 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -13.79% in the last 52 weeks. The beta is 1.88, so Immunic 's price volatility has been higher than the market average.
Beta | 1.88 |
52-Week Price Change | -13.79% |
50-Day Moving Average | 1.1 |
200-Day Moving Average | 1.29 |
Relative Strength Index (RSI) | 43.67 |
Average Volume (20 Days) | 971.26K |
Income Statement
Revenue | n/a |
Gross Profit | -111.00K |
Operating Income | -99.22M |
Net Income | -93.61M |
EBITDA | -99.11M |
EBIT | n/a |
Earnings Per Share (EPS) | -2.11 |
Balance Sheet
The company has 46.67M in cash and 1.33M in debt, giving a net cash position of 45.34M.
Cash & Cash Equivalents | 46.67M |
Total Debt | 1.33M |
Net Cash | 45.34M |
Retained Earnings | -410.89M |
Total Assets | 64.76M |
Working Capital | 39.91M |
Cash Flow
In the last 12 months, operating cash flow was -70.83M and capital expenditures -334.00K, giving a free cash flow of -71.16M.
Operating Cash Flow | -70.83M |
Capital Expenditures | -334.00K |
Free Cash Flow | -71.16M |
FCF Per Share | -1.61 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
IMUX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -211% |
FCF Yield | -78.68% |
Analyst Forecast
The average price target for IMUX is $10, which is 900% higher than the current price. The consensus rating is "Buy".
Price Target | $10 |
Price Target Difference | 900% |
Analyst Consensus | Buy |
Analyst Count | 7 |
Stock Splits
The last stock split was on Apr 15, 2019. It was a backward split with a ratio of 1:40.
Last Split Date | Apr 15, 2019 |
Split Type | backward |
Split Ratio | 1:40 |
Scores
Altman Z-Score | -12.31 |
Piotroski F-Score | 1 |